COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, March 1–June 30, 2020. (9th November 2020)

• Record Type: Journal Article
• Authors: Acosta, Anna M; Mathis, Adria L; Budnitz, Daniel S; Geller, Andrew I; Chai, Shua J; Alden, Nisha B; Meek, James; Anderson, Evan J; Ryan, Patricia; Kim, Sue; Como-Sabetti, Kathryn; Torres, Salina; Dufort, Elizabeth; Bennett, Nancy M; Billing, Laurie M; Sutton, Melissa; Keipp Talbot, H; George, Andrea; Pham, Huong; Hall, Aron J; Fry, Alicia; Garg, Shikha; Kim, Lindsay
• Is Part Of: Open forum infectious diseases. Volume 7:Number 11(2020)
• Publication Date: 2020-11-09
• Subjects: coronavirus -- hospitalization -- therapeutics; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa528
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Using a coronavirus disease 2019 (COVID-19)–associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1–June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased. Abstract : Using data collected from a national surveillance network for COVID-19-associated hospitalizations, we describe inpatient COVID-19 investigational treatment use from March-June, 2020. Overall, hydroxychloroquine, azithromycin and remdesivir were used frequently. Over time, use of hydroxychloroquine and azithromycin declined, while remdesivir increased.